The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A
Haemophilia · 2023
DOI: 10.1111/hae.14877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2023. Verfasst von Tomoko Onishi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Chugai Pharmaceutical Co., Ltd., Grant-in-Aid for Scientific Research.
Abstract (Originalsprache)
Introduction
Emicizumab is used as hemostatic prophylaxis for patients with hemophilia A (PwHA), irrespective of the presence of inhibitors. Although bacterial infection can lead to a procoagulant state, there is limited information on coagulation and fibrinolysis potentials in emicizumab‐treated PwHA and on the use of anticoagulants in such cases.
Aim
We examined whether anticoagulants affect the coagulation and fibrinolysis potentials in plasma from PwHA spiked with emicizumab.
Methods
Plasma from PwHA was in vitro supplemented with emicizumab (50 μg/mL; emi‐plasma) and anticoagulants (recombinant thrombomodulin (rTM), nafamostat mesylate (NM), unfractionated heparin (UFH), or low‐molecular‐weight heparin (LMH)). PwHA plasma spiked with rFVIII (1 IU/mL) was used as a reference (ref‐plasma). The coagulation and fibrinolysis potentials in plasma was measured by thrombin and plasmin generation assay (T/P‐GA) and clot‐fibrinolysis waveform analysis (CFWA).
Results
In T/P‐GA and CFWA, coagulation potentials (maximum coagulation velocity; |min1|, and peak thrombin; Th‐Peak) in plasma rose with increasing concentrations of emicizumab and rFVIII, but fibrinolytic potentials (peak plasmin; Plm‐Peak, and maximum fibrinolytic velocity; |FL‐min1|) remained unchanged. Adding rTM, NM, and UFH to emi‐plasma suppressed coagulation and fibrinolysis potentials, similar to ref‐plasma. Regarding the heparin, UFH and LMH inhibited the improved coagulation in emi‐plasma. UFH inhibited fibrinolysis as well, but LMH did not.
Conclusions
Anticoagulants could exhibit the inhibitory effects on the coagulation and fibrinolysis potentials in plasma from PwHA spiked with emicizumab, similar to those in normal plasma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
- Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.
ORCID-Profile: Tomoko Onishi, Keiji Nogami
Förderung
- Chugai Pharmaceutical Co., Ltd.
- Grant-in-Aid for Scientific Research
Zitieren
APA
Onishi, T., Harada, S., Shimo, H., Tashiro, Y., Soeda, T., & Nogami, K. (2023). The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A. Haemophilia. https://doi.org/10.1111/hae.14877
Vancouver
Onishi T, Harada S, Shimo H, Tashiro Y, Soeda T, Nogami K. The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A. Haemophilia. 2023. doi:10.1111/hae.14877
BibTeX
@article{Onishi2023,
author = {Onishi, Tomoko and Harada, Suguru and Shimo, Hanako and Tashiro, Yoshihito and Soeda, Tetsuhiro and Nogami, Keiji},
title = {The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A},
journal = {Haemophilia},
year = {2023},
doi = {10.1111/hae.14877}
}
EUVIMED